Emmes Acquires Casimir to Strengthen Rare Disease Research Capabilities
May 10, 2022
Emmes, a portfolio company of Behrman Capital, has acquired Casimir, a Plymouth, Massachusetts–based CRO specializing in rare disease outcome measures and virtual/remote assessments. The add-on expands Emmes' rare disease center of excellence and brings Casimir's clinical outcomes technology and expertise into Emmes' global service offerings; terms were not disclosed.
- Buyers
- Emmes, Behrman Capital
- Targets
- Casimir
- Platforms
- Emmes
- Industry
- Healthcare Services
- Location
- Massachusetts, United States
- Transaction Type
- Addon
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.